Merck spin-out to acquire Forendo Pharma

Sunday 14 November 2021
Country

United States

Organon, a recent spin-off of Merck & Co Inc, is to expand its portfolio of assets in reproductive health with the acquisition of Forendo Pharma Ltd of Finland. Organon has agreed to pay up to $954 for the Finnish company, a figure that includes potential outlays for the achievement of certain development, regulatory and commercial milestones. Forendo’s lead product is being developed for endometriosis, a chronic condition that affects up to one in 10 women of reproductive age.